Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million

Agreement provides significant, non-dilutive capital to Novavax, further enabling the Company to advance its corporate growth strategy of driving value from its pipeline assets and proven technology platform Provides Novavax with $190 million cash payment in 2024 and additional $10...